Skip to main content
SpringerLink
Log in

Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Mesna, a reactive thiol, often encounters cisplatin and carboplatin in combination protocols involving oxazaphosphorines and platinum drugs. This co-administration might be unfavorable based on the inactivation of platinum drugs by thiol groups in vitro. We investigated whether mesna influences the pharmacokinetics of platinum drugs when co-administered with cisplatin or carboplatin. The pharmacokinetics of platinum drugs were investigated in 18 pediatric patients receiving either cisplatin or carboplatin in a combination with or without mesna. In cisplatin patients, a decrease in the distribution clearance of total platinum was observed when mesna was co-administered (CL d, 2.2±0.1 mL/min·kg; n=3), compared to cisplatin without mesna (CL d, 4.8±1.5 mL/min·kg; n=5) (p=0.029, t-test). This might have been caused by an influence of mesna in slowing down the protein binding of cisplatin since a trend (p=0.057) in prolonged distribution half-life of total platinum was also observed when mesna was present ({ie9-1}, 65±21 min; n=3) compared to cisplatin without mesna ({ie9-2}, 32±18 min; n=5). However, the impact of these changes on the area under the concentration time curve (AUC), total clearance (CL t), and volume of distribution (V) for total platinum and ultrafilterable platinum species was hardly noticeable. In carboplatin patients, when mesna was co-administered: AUC (2.5±0.4 mg·min/mL·400 mg/m2; n=5) CL t, (6.8±5.1 mL/min·kg; n=6), and V (0.7±0.4 L/kg; n=6) for ultrafilterable platinum species were not significantly different from when carboplatin were administered without mesna: AUC (2.3±1.3 mg·min/mL·400 mg/m2; n=4), CL t(5.8±4.6 mL/min·kg; n=5), and V (1.1±1.1 L/kg; n=5). Hence, mesna does not significantly influence the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brock N, Pohl J, Stekar J, Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 1982;18(12):1377–1387.

    Article  PubMed  CAS  Google Scholar 

  2. Shaw IC, Graham MI. Mesna a short review. Cancer Treat Rev 1987;14(2):67–86.

    Article  PubMed  CAS  Google Scholar 

  3. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57(3):293–308.

    Article  PubMed  CAS  Google Scholar 

  4. Howe-Grant ME, Lippard SJ. Aqueous platinum (II) chemistry; binding to biological molecules. In: Helmut S (ed). Metal Ions in Biological Systems. New York: Marcel Dekker Inc.; 1980, pp. 63–125.

    Google Scholar 

  5. Wolff JE, Egeler RM, Anderson R, Ujack E, Iceton S, Coppes MJ. Mesna inactivates platinum agents in vitro. Antican Res 1998;18(6A):4077–4081.

    CAS  Google Scholar 

  6. Boven E, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 2002;38(8):1148–1156.

    Article  PubMed  CAS  Google Scholar 

  7. Sadowitz PD, et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metab Dispos 2002;30(2):183–190.

    Article  PubMed  CAS  Google Scholar 

  8. Dorr RT, Lagel K. Interaction between cisplatin and mesna in mice. J Cancer Res Clin Oncol 1989;115(6):604–605.

    Article  PubMed  CAS  Google Scholar 

  9. Hausheer FH, et al. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Sem Oncol 1998;25(5):584–599.

    CAS  Google Scholar 

  10. Wils J, et al. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Antican Drugs 1999;10(3):257–261.

    Article  CAS  Google Scholar 

  11. Culine S, Theodore C, Bekradda M, Farhat F, Terrier-Lacombe MJ, Droz JP. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II)/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 1997;20(2):184–188.

    Article  PubMed  CAS  Google Scholar 

  12. Polyzos A, et al. Second-line chemotherapy with cisplatinifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide. J Chemother 1999;11(2):144–149.

    PubMed  CAS  Google Scholar 

  13. Graziano SL, et al. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;14(2–3):315–329.

    Article  PubMed  CAS  Google Scholar 

  14. Fetscher S, et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. Ann Oncol 1999;10(5):605–607.

    Article  PubMed  CAS  Google Scholar 

  15. Gerke P, Filejski W, Robins HI, Wiedemann GJ, Steinhoff J. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. J Cancer Res Clin Oncol 2000;126(3):173–177.

    Article  PubMed  CAS  Google Scholar 

  16. Edmonson JH, et al. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest 2001;19(6):597–602.

    Article  PubMed  CAS  Google Scholar 

  17. Meyer WH, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude children’s research hospital os-91 trial. J Clin Oncol 2001;19(1):171–182.

    PubMed  CAS  Google Scholar 

  18. Gangopadhyay SB, Roendigs A, Kangarloo SB, Krebs B, Wolff JE. Cellular accumulation determines the activity of three novel tricyclic platinum agents. Antican Res 2001;21(3B):2039–2043.

    CAS  Google Scholar 

  19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Dekker, 1982.

    Google Scholar 

  20. James CA, Mant TG, Rogers HJ. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 1987;23(5):561–568.

    PubMed  CAS  Google Scholar 

  21. Goren MP, et al. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 1998;16(2):616–621.

    PubMed  CAS  Google Scholar 

  22. Ormstad K, Uehara N. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 1982;150(2):354–358.

    Article  PubMed  CAS  Google Scholar 

  23. Leeuwenkamp OR, van der Vijgh WJ, Neijt JP, Pinedo HM. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP. Cancer Chemother Pharmacol 1990;27(2):111–114.

    Article  PubMed  CAS  Google Scholar 

  24. Obrocea MM, et al. In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine. Oncol Rep 1998;5(6):1493–1498.

    PubMed  CAS  Google Scholar 

  25. Peng B, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 1997;33(11):1823–1828.

    Article  PubMed  CAS  Google Scholar 

  26. Newell DR, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children’s Cancer Study Group. J Clin Oncol 1993;11(12):2314–2323.

    PubMed  CAS  Google Scholar 

  27. Leeuwenkamp OR, Neijt JP, van der Vijgh WJ, Pinedo HM. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. Eur J Cancer 1991;27(10):1243–1247.

    Article  PubMed  CAS  Google Scholar 

  28. Vermorken JB, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986;39(2):136–144.

    Article  PubMed  CAS  Google Scholar 

  29. Barnham KJ, Djuran MI, del Socorro Murdoch P, Ranford JD, Sadler PJ. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorgan Chem 1996;35(4):1065–1072.

    Article  CAS  Google Scholar 

  30. Natarajan G, Malathi R, Holler E. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol 1999;58(10):1625–1629.

    Article  PubMed  CAS  Google Scholar 

  31. Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemother Pharmacol 1996;38(5):395–400.

    Article  PubMed  CAS  Google Scholar 

  32. Murry DJ. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997;17(5 Pt 2):140S-145S.

    PubMed  CAS  Google Scholar 

  33. Notari RE. Biopharmaceutics and clinical pharmacokinetics: an introduction. 4th rev. and expand ed. New York: Dekker, 1987.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Faculty of Medicine, University of Calgary, Tom Baker Cancer Centre, T2N 4N2, Calgary, Alberta, Canada

    Shahbal B. Kangarloo, Rachel M. Syme & Stefan Glück

  2. Cancer Biology Research Group, University of Calgary, Alberta, Canada

    Suman B. Gangopadhyay

  3. Klinik St. Hedwig, Steinmetzstraße 1-3, 93049, Regensburg, Germany

    Johannes E. A. Wolff

Authors
  1. Shahbal B. Kangarloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suman B. Gangopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel M. Syme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johannes E. A. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan Glück
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Glück.

Additional information

These two authors share senior authorship.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kangarloo, S.B., Gangopadhyay, S.B., Syme, R.M. et al. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol 21, 9–19 (2004). https://doi.org/10.1385/MO:21:1:09

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:21:1:09

Key Words

Search

Navigation